Opthalmic Pharmaceutical Drugs
| Product Code | GIA00249 |
| Publication Date | October 2010 |
| Publisher | Global Industry Analysts |
| Product Type | Report |
| Pages | 565 |
| ISBN Number | not applicable |
Opthalmic Pharmaceutical Drugs
This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ million by the following Therapeutic Categories:
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye, and Others.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 95 companies including many key and niche players such as Akorn, Inc., Alcon, Inc., Allergan, Inc., Alimera Sciences, Inc., Bausch & Lomb, Inc., Genvec, Inc., GlaxoSmithKline Plc, Inspire Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Ophthalmics, Opko Health, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., QLT, Inc., Santen Pharmaceutical Co., and Santen Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Contents
- 1.Introduction, Methodology & Product Definitions
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- 2.Industry Overview
- Present Scenario and Outlook
- Current & Future Analysis
- Patent Expiries to Check Market Growth
- New Drugs to Sustain Growth
- A Curtain Raiser
- Drugs Developed in The Recent past
- What The Future Holds in Store?
- Where Does The Opportunity Lie?
- in The Shifting Demographics
- Which Disease Segment Offers Abundant Opportunities for R&d Initiatives
- Leading Companies & Their Areas of Research Interest/Focus
- Business Opportunities in Ophthalmology: A Fact Sheet
- Impediments in Picking The Ripe & Low Hanging Opportunities
- Low Patient Compliance
- What's The Antidote to Low Patient Compliance?
- Innovation in Ophthalmic Pharmaceuticals: How Does IT Help Patients?
- An Unequivocal Discussion about Ocular Drug Design and Delivery
- Why Understanding of The Metabolic Activity of The Eye Is Important?
- Pitfalls of Traditional Ocular Treatment
- Ophthalmic Drug Delivery: A Recapitulation of Facts
- Antidotes to Low Delivery of Ocular Drugs & High Side Effects
- Prodrug
- Soft Drugs (Sds)
- Soft Corticosteroids
- Drug Penetration Enhancers
- Chitosan Based Drugs & Drug Delivery Systems
- How Chitosan Is Used to Improve Ocular Drug Retention on The Eye's Surface?
- The Future of Ophthalmic Drug Delivery
- A Straight Talk about Ophthalmic Drug Delivery Technologies
- High Flying Expectations of Blistering Pace of Drug Development Grounded
- First Generation Advancements Made in Ocular Drugs
- Second Generation Advancements Made in Ocular Drugs
- Limiting Factors
- 3.Market Dynamics
- Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty
- Ophthalmic Inserts Flaunt The Potential to Eclipse The Popularity of Eye Drops
- Rising Incidences of Glaucoma: A Business Case for Ophthalmic Drugs
- Lack of Awareness Creates Huge Burden
- Financial Costs of Glaucoma Plague Developed and Developing Countries
- Aging Population & Environmental Factors Drive Growth
- Increase in Healthcare Spending
- Opportunities Abound in The Developing Countries
- Innovative Products Lend Traction to Growth
- Reimbursements: “under The Umbrella”
- Pricing Statistics on Select Ophthalmic Drugs in The US (2006) – A Perspective Builder
- Price Changes for Select Ophthalmic Drugs in The Year 2005
- 4.An Overview of Ophthalmic Drugs
- Anti Viral Drugs
- Adenoviral Infections
- Herpes Simplex Virus
- Herpes Zoster (Varicella Zoster Disease)
- Corticosteroids
- Loteprednol
- Prednisolone
- Dexamethasone
- Fluorometholones
- Fluorometholone Alcohol
- Fluorometholone Acetate
- Rimexolone
- Clinical Efficacy of Steroids
- Topical Corticosteroid Drugs
- Tapering of Steroid Intake
- Non-Steroids Anti Inflammatory Drugs (Nsaid)
- Use of Topical Nsaids
- Topical & Systemic Nsaids
- Ketorolac: A Potent Nsaid
- Non-Steroidal Anti-Inflammatory Drugs
- Antibiotics
- Sodium Sulfacetamide
- Sulfisoxazole
- Bacitracin
- Bacitracin and Polymyxin B: A Powerful Duo
- Bacitracin, Polymyxin B and Neomycin: Three to Tango
- Trimethoprim with Polymyxin B
- Chloramphenicol
- Erythromycin
- Gentamicin and Tobramycin
- Fluoroquinolones
- Types of Fluoroquinolones
- Ciprofloxacin
- Gatifloxacin
- Levofloxacin
- Moxifloxacin
- Ofloxacin
- Topical Antibiotic Drugs
- Ophthalmic Antihistamines
- Azelastine
- Emedastine
- Epinastine
- Ketotifen
- Olopatadine
- Ophthalmic Mast-Cell Stabilizers
- Cromolyn
- Nedocromil Sodium
- Pemirolast
- Drugs to Treat Glaucoma
- Beta-Adrenergic Blockers or "beta Blockers"
- Timolol
- Levobunolol
- Carteolol
- Metipranolol
- Betaxolol
- Alpha-Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Acetazolamide
- Dorzolamide
- Acetazolamide & Dorzolamide: How Good Is The Combo?
- Miotics
- Prostaglandins
- Mydriatics & Cycloplegics
- Side Effects
- over-The-Counter (Otc) Ophthalmic Preparations
- Artificial Tears
- Lubricating Ointments
- Mast Cell Stabilizers
- Antihistamines
- Phenylephrine
- Naphazoline
- Xylometazoline
- Astringents
- over-The-Counter Ophthalmic Preparations
- A Directory Listing of Major Ophthalmic Pharmaceutical Drugs
- Formulary Anti- Glaucoma Drugs
- Non-Formulary Anti- Glaucoma Drugs
- Formulary Topical Anti-Glaucoma Drugs
- Formulary Ophthalmic Antiinfective/Corticosteroids Drugs
- Non-Formulary Ophthalmic Antiinfective/ Corticosteroids Drugs
- Formulary Ophthalmic Corticosteroid Drugs
- Non-Formulary Ophthalmic Corticosteroid Drugs
- Formulary Ophthalmic Topical Antibacterial Drugs
- Non-Formulary Ophthalmic Topical Antibacterial Drugs
- Formulary Ophthalmic Topical Antiviral Drugs
- Other Ophthalmic Formulary Drugs
- Other Ophthalmic Non-Formulary Drugs
- Pipeline Drugs
- 5.Ophthalmic Disorders: A Freeze Frame
- The Human Eye: A Remarkable & Intriguing Organ of Sight
- The Outer Layer
- The Middle Layer
- The Inner Layer
- Common Ophthalmic Disorders: An Exposition
- Cataract
- Causes
- Types of Cataract
- Treatment Strategies
- How Widespread Is The Disease?
- Glaucoma
- Who's at Risk?
- Types of Glaucoma
- Primary Open Angle Glaucoma (Poag)
- Acute Angle-Closure Glaucoma (Aacg)
- Congenital Glaucoma
- Secondary Glaucoma
- Treatment Strategies
- Anti- Glaucoma Ophthalmic Drugs
- Table 1: Global Market for Glaucoma Pharmaceuticals (2008): Percentage Value Share Breakdown of Leading Players - Pfizer, Inc., Allergan, Inc., Merck & Co., Alcon, Ista Pharmaceuticals and Others (Includes Corresponding Graph/Chart)
- Table 2: Leading Glaucoma Pharmaceutical Products in The Global Market (Excluding US) (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/ Xalcom, Cosopt/Trusopt, Travatan/ Extravan, Lumigan/Ganfort, Alphagan/Combigan, Timoptic/ Xe, Generic Timolol and Others (Includes Corresponding Graph/Chart)
- How Widespread Is The Disease?
- Table 3: Prevalence of Glaucoma in The World: Year 1999 and 2006 A Comparison (in 000 Individuals) (Includes Corresponding Graph/Chart)
- Is Marijuana A Potential Cure?
- Age-Related Macular Degeneration (Amd)
- Types of Amd
- Dry Amd (Non-Neovascular)
- Wet Amd (Neovascular)
- Causes
- Treatment Strategies
- Nutrition & Amd
- Diabetic Retinopathy
- How Widespread Is The Disease?
- Table 4: Diabetic Retinopathy Patient Prevalence in The US by Diabetes Type: 2006-2015 (in Thousand Patients) (Includes Corresponding Graph/Chart)
- Table 5: Diabetic Retinopathy Patient Prevalence in The US by Age Group: 2006-2012 (Includes Corresponding Graph/Chart)
- Table 6: Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in The US by Age Group: 2006-2012 (Includes Corresponding Graph/Chart)
- Treatment Strategies
- Market Awaits First Approved Drug; off-Label Use Continues
- Diabetic Retinopathy Drug Market to Post Dramatic Growth
- Select Pipeline Drugs in Diabetic Retinopathy Market
- Additional Trials Delay Arxxant's Launch
- Lucentis Shows Promise in Diabetic Retinopathy Treatment
- Pycnogenol Continues to Appeal to Researchers
- Robo4 Protein – A Potential Therapeutic for Diabetic Retinopathy
- Bevacizumab Bodes Potential as An Adjunct to Surgery Pdr Treatment
- Ocular Allergies
- Treatment Strategies
- Immunotherapy: A Popular Anti-Allergy Treatment Approach
- Ocular Inflammation: A Symptom of Ocular Allergies
- How Can Allergies Be Prevented?
- Conjunctivitis (Pink Eye)
- Types of Conjunctivitis
- Pathogenesis
- Treatment Strategies
- Keratitis
- Types of Keratitis
- Treatment Strategies
- Dry Eye
- Why Are Tears So Crucial for Normal Eye Health?
- What Causes Dry Eye?
- Treatment Strategies
- Refractive Errors
- Causes for Refractive Error
- Treatment for Refractive Errors
- Cost of Treatment
- Factors Contributing to The Difference in Surgery Costs
- 6.Fda Approvals and Product Launches
- Zymaxid Obtains US Fda Approval
- Carco Introduces Azelastine Ophthalmic Solution, 0.05%
- Fera Pharmaceuticals Launches Neptazane Tablets
- Banyu Pharmaceutical Introduces Cosopt Combinational Ophthalmic Solution
- Bausch & Lomb Launches Soothe Xtra Hydration Eye Drops in The US
- Akorn Secures Fda Clearance for Erythromycin Ophthalmic Ointment
- Teva Launches New Dorzolamide Hydrochloride Ophthalmic Solution
- Caraco Pharmaceutical Laboratories Introduces New Ophthalmic Drug
- Auxano Diagnostics Introduces Novel Point-of-Care Indicator System
- Senju Pharmaceutical to Launch Lumigan® Ophthalmic Solution in Japan
- Sirion Receives Fda Approval for Zirgan
- Ista Pharmaceuticals Obtains Fda Approval for Beprevetm
- Aton Pharma Reintroduces Timoptic® in Ocudose®
- Novagali Pharma Obtains Fda Clearance for Phase Iii Study for Catioprost
- Allergen Obtains Fda Approval for New Ophthalmic Product
- Akorn Receives Fda Approval for Ciprofloxacin Hcl Ophthalmic Solution Usp
- Akorn Introduces Akten Gel
- Sirion Launches Topical Ophthalmic Drug
- Fdc Obtains Fda Approval for Ciprofloxacin Ophthalmic Solution
- Novagali Pharma to Introduce Cationorm® in France
- Allergan Obtains Fda Clearance for Combigan
- 7.Fda Approvals and Product Approvals Launches in The Recent past – A Perspective Builder
- Novagali Obtains Fda Approval of Nova22007 Ind for Ph Iii Trial
- Alimera Conducts Phase Iii Medidur Trial
- Ista Pharmaceuticals Files Nda for Xibrom™ Qd
- Azasite Receives Fda Approval
- Inspire Pharmaceuticals Rolls out Azasite™ for Ocular Infections
- Alimera Sciences Receives Fda Approval
- Alcon Receives Approval for Vegamox™ Ophthalmic Solution in Japan
- Alcon Receives Marketing Approval for Patanol® in Japan
- Allergan Receives Fda Approval for Lumigan®
- Allergan's Ganfort® Receives Pan European License
- Pfizer Receives Approval from Ec to Market Macugen®
- Akorn Gets Nod for Conducting Clinical Trial of Ak-1015
- Genentech ‘s Lucentis Receives Fda Approval
- Macusight Receives Fda Approval for Ind Application of Sirolimus
- Sami Labs Receives Approval for Ocufors
- Toyamo and Nidek Obtain Manufacturing Approval for Quinolone Ophthalmic Solutions
- Reckitt Benckiser Launches Two Eye Care Products
- Alcon Launches Duotrav for Glaucoma Treatment
- Macugen® Receives European Regulatory Approval
- Rohto Pharmaceutical Launches Switch Otc Ophthalmic Drug
- Indoco Remedies to Launch Ophthalmic Drugs in America
- Alcon's Nevanac Receives Fda Approval
- Fougera Obtains Approval for Metrogel®
- Allergan's Alphagan P Receives Fda Approval
- Santen Obtains Approval for Manufacturing and Marketing Papilock
- Akorn Launches Ophthalmic Drug Products
- Alpharx Formulates The Ophthalmic Product, Binoxan™
- Alimera Sciences Introduces Online Consumer Ordering Facility
- Fougera Adds Two Novel Products to Its Ophthalmic Product Line
- Micro Vision Launches Anti-Glaucoma Drugs
- Alcon Receives Fda Approval for Adding Susceptible Pathogens to Vigamox
- Bol Receives Fda Approval for Ofloxacin
- Hi-Tech Pharmacal Receives Fda Clearance for Ofloxacin Ophthalmic Solution
- Vision Blue and Dorc International Receives Fda Approval for Trypan Blue
- Pfizer Receives Fda Nod for Macugen®
- Bausch & Lomb Bags Fda Approval for Its Zylet™
- Ista Pharmaceuticals Launches Istalol for Glaucoma Treatment in The US
- Falcon Unveils Trifluridine Ophthalmic Solution, 1%
- Alimera Sciences Unveils Soothe™ Emollient Eye Drops
- Novartis Introduces Zaditen in Japan
- Falcon Releases Brimonidine Tartrate Ophthalmic Solution, 0.2%
- Alcon Receives Approval for Olopatadine (Patanol)
- Pharmacia Receives Fda Approval for Latanoprost Ophthalmic Solution
- US Fda Approves Allergan's New Acular Ls 0.4% for Ocular Pain Reduction
- Allergan Obtains Fda Approval for Zymar
- Taiwanese Researchers Introduces Thermosensitive Ophthalmic Drop
- Alcon Introduces Systane Lubricant Eye Drops
- Allergan Releases Restasis for Dry Eye Treatment
- Biosyntrx Launches Biotears
- Novartis to Introduce Pirenzepine Ophthalmic Gel
- 8.Recent Industry Activity
- Bausch & Lomb Takes over Zirgan®
- Inspire and Santen Secure Japanese Approval for Diquas
- Asahi Kasei Pharma and Altheos Enter into License Agreement
- Opko Health Takes over Pharmacos Exakta
- Alcon Acquires Rights of Two Ophthalmic Pharmaceutical Products of Sirion
- Qlt Secures Rights from Othera Pharmaceuticals
- Novartis Acquires 77% Stake in Alcon
- Pfizer Acquires Wyeth
- Pieris Collaborates with Allergan to Treat Ocular Disorders
- Bausch & Lomb Takes over Commercial Assets of Tubilux
- I-Therapeutix Changes Its Name to Ocular Therapeutix
- Alcon Signs Collaborative Research Agreement with Astrazeneca
- Fera Pharmaceuticals Takes over Seven Ophthalmic Ointments of Fougera
- Bausch & Lomb Obtains Approval for Novel Ophthalmic Product
- Alcon to Set up Manufacturing Facility in Singapore
- Inspire Pharmaceuticals Selects Clinipace to Conduct Phase Ii Clinical Trials
- Regeneron and Bayer to Extend Global Development Collaboration
- Sucampo Obtains Rights to Commercialize Rescula
- Santen and Merck Inks Licensing Agreement
- Insite Vision Inks Licensing and Distribution Agreement with Nitten
- Opko Terminates Phase Iii Trial of Bevasiranib
- Sirion Therapeutics Signs Agreement with Advanced Vision Research
- Bausch & Lomb and Pfizer Ink Co-Promotion Agreement
- Nanoviricides Inks Material Transfer Agreement for Ophthalmic Antiviral
- Macuclear Partners with Mystic for Clinical Trials
- Sohm Inks Private Label and Development Agreement with Indian Company
- Adeona Forms Research Collaboration with Nnri
- Santen Receives Approval for Tapros from Mhlw
- Otsuka and Acucela Ink Definitive Co-Development Deal for Rebamipide
- Canadian Bio Med Systems Obtains Licensing Rights for Two Ophthalmic Products
- Novartis Acquires Minority Stake in Alcon from Nestle
- Opko Acquires Development and Commercialization Rights to Doxovir™
- Insite Vision Inks Licensing and Distribution Agreement with Essex
- Argentis Pharmaceuticals Obtains License for New Ophthalmic Drug
- Opko Health Finalizes Vidus Ocular Take over
- Insite Vision Inks Licensing and Distribution Agreement with Biem
- Bausch & Lomb Inks Collaborative Research Agreement with Galapagos
- Prp and Jerini Ink License and Development Agreement with Jerini Ophthalmic
- Akorn Inks Manufacturing and Supply Agreement with A US Company
- Sirion and Bridge Pharma Sign Licensing Agreement
- Nicox Extends Collaboration Agreement with Pfizer
- Bausch & Lomb Acquires Iol Maker, Eyeonics
- Akorn Inks Manufacture &supply Agreement for Ophthalmic Solution
- Crystalgenomics Enters into R&d Agreement with Bausch & Lomb
- 9.Corporate Activity in Recent past – A Perspective Builder
- Genaera Corporation Quits Evizon Clinical Trials
- Eyetech Inc Divests Anti-Platelet Derived Growth Factor (Pdgf) Aptamer Program
- Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs
- Bausch & Lomb Acquire Soothe Products from Alimera
- Froptix, Acuity, Exegenics Merge to Form Opko Corporation
- Alimera, Emory Collaborate over Potential Ophthalmic Treatments Using Novel Antioxidants
- Santen Signs Agreement with Vistakon Pharmaceuticals for US Launch of Iquix®
- Inspire Pharmaceuticals Rolls out Azasite™ for Ocular Infections
- Qlt Takes over Forsight Newco Ii, Inc
- Phase Iv Clinical Trials of Macugen®
- Results of Phase Ii Clinical Trials – Macugen®
- Bausch & Lomb Purchases Otc Allergy Drugs of Alimera
- Phase Ii Trial of Acuity Pharmaceutical's Bevasiranib
- Advanced Refractive Technologies Acquires A Subsidiary of Utek Corporation
- Sirion Therapeutics Acquires Sytera
- Teva Pharmaceuticals Acquires Ivax
- Alcon Enters into An Agreement with Amgen
- Qlt Signs An Agreement with Retinagenix
- Nicox Enters into Licensing Agreement with Pfizer
- Occulogix Signs Agreement to Acquire Solx
- Ista Receives License from Senju for Allergy Treatments
- Acuity Receives License for Nchlorotaurine
- Akorn and Avr Enter into Commercial Manufacturing & Supply Agreement
- Lantibio Signs Agreement with Trb Chemedica
- Argentis and Southern College of Optometry Enter into Agreement
- Bausch & Lomb Enters into Marketing Agreement with Novartis
- Santen Pharmaceuticals and Ube Industries to Develop Glaucoma Therapy Jointly
- Santen Pharmaceutical and Cytopathfinder Signs An Agreement
- Kalypsys Inks An Agreement with Alcon, Inc
- Combination Rx Enters into A Collaboration Agreement with Fovea
- Par Pharmaceutical Joins Force with Spectrum Pharmaceuticals
- Isotechnika Sells Eye Drug Rights to Lux Biosciences
- Alimera Sciences Collaborates with Cynacon
- Novartis Inks An in-Licensing Agreement with Otsuka
- Alimera Sciences Commences Phase Iii Trials for Medidur™
- Surmodics Acquires Innorx
- Bausch & Lomb Acquires Shandong Chia Tai Freda Pharmaceutical Group
- Osi Pharmaceuticals Takes over Eyetech Pharmaceuticals
- Pfizer Acquires Angiosyn
- Bausch & Lomb Collaborates with Ptc Therapeutics
- Amri Enters into Research Collaboration with Alcon
- Bausch & Lomb Bags License from Cephalon
- Pediamed and Allergan Sign A Co-Promotion Agreement
- Surmodics Bags Option to Acquire Exclusive Rights from Rutgers University
- Sankyo Co. and Santen Pharmaceutical Sign Agreement
- Acuity Pharmaceuticals Enters into Agreement with Intradigm Corporation
- Apotex Inks Marketing Agreement with Akorn
- Novartis Enters into An Agreement with Senju Pharmaceutical
- Novartis Strikes A Licensing Deal with Otsuka Pharmaceutical
- Custom Rx Recalls Trypan Blue 0.06% Ophthalmic Solution
- Amo Takes over Visx
- Advanced Medical Optics Acquires Ophthalmic Surgical Business of Pfizer
- Santen to Take over Marketing Rights of Rescula from R-Tech Ueno
- Alimera Sciences Inks Co-Promotion Agreement with Vistakon Pharmaceuticals
- Akorn Inks A Purchase and Supply Agreement with Fdc
- Ista Pharmaceuticals Receives Marketing License from Senju Pharmaceuticals
- Pfizer Inc Acquires Pharmacia Corp
- Allergan Takes over Oculex Pharmaceuticals
- Allergan Enters into An Agreement with Acadia
- 10.Focus on Select Global Players
- Akorn, Inc. (USA)
- Alcon, Inc. (Switzerland)
- Allergan, Inc. (USA)
- Alimera Sciences, Inc. (USA)
- Bausch & Lomb, Inc. (USA)
- Genvec, Inc. (USA)
- Glaxosmithkline Plc. (UK)
- Inspire Pharmaceuticals, Inc. (USA)
- Ista Pharmaceuticals, Inc. (USA)
- Merck & Co., Inc. (USA)
- Novartis Ophthalmics (Canada)
- Opko Health, Inc. (USA)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- Pfizer, Inc. (USA)
- Qlt, Inc. (Canada)
- Santen Pharmaceutical Co. (Japan)
- Santen Inc. (US)
- 11.Global Market Perspective
- Table 7: World Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 8: World Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 9: World 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- Table 10: World Recent past, Current and Future Analysis for Glaucoma Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 11: World Historic Review for Glaucoma Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 12: World 11-Year Perspective for Glaucoma Treatment Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- Table 13: World Recent past, Current and Future Analysis for Ophthalmic Anti-Allergy Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 14: World Historic Review for Ophthalmic Anti-Allergy Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 15: World 11-Year Perspective for Ophthalmic Anti-Allergy Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- Table 16: World Recent past, Current and Future Analysis for Ophthalmic Anti-Infective Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 17: World Historic Review for Ophthalmic Anti-Infective Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 18: World 11-Year Perspective for Ophthalmic Anti-Infective Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- Table 19: World Recent past, Current and Future Analysis for Dry Eye Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 20: World Historic Review for Dry Eye Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 21: World 11-Year Perspective for Dry Eye Treatment Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- Table 22: World Recent past, Current and Future Analysis for Ophthalmic Anti-Inflammatory Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 23: World Historic Review for Ophthalmic Anti-Inflammatory Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2007 (Includes Corresponding Graph/Chart)
- Table 24: World 11-Year Perspective for Ophthalmic Anti-Inflammatory Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- Table 25: World Recent past, Current and Future Analysis for Back of Eye Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 26: World Historic Review for Back of Eye Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 27: World 11-Year Perspective for Back of Eye Treatment Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- Table 28: World Recent past, Current and Future Analysis for Other Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 29: World Historic Review for Other Ophthalmic Treatment Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 30: World 11-Year Perspective for Other Ophthalmic Treatment Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
- 12.The United States
- A. Market Analysis
- Outlook
- Recession Relights Sales of Otc Drugs in Pharmaceutical Industry
- Emphasis on Greater Awareness about Ophthalmic Disorders
- Growth Drivers in A Capsule
- Impediments to Growth
- Market Fact Sheet
- Glaucoma Market: A Primer
- Patent Expiries of Key Glaucoma Drugs
- Awareness among Patients
- High Costs
- Treatment Patterns Adopted by Doctors
- The All Consuming Issue of Compliance
- Drug Brands & Their Patient Compliance Score
- Market Share Statistics
- Table 31: The US Market for Ophthalmic Pharmaceutical Drugs (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Allergan, Novartis Pharmaceutical, Pfizer/Osi Pharmaceuticals, Bausch & Lomb Pharmaceuticals, and Others (Includes Corresponding Graph/Chart)
- Table 32: The US Market for Glaucoma Pharmaceutical Products by Leading Drugs (2008 & 2009): Market Share Breakdown in Terms of Prescription Volume for Xalatan, Lumigan, Alphagan P, Travatan and Others (Includes Corresponding Graph/Chart)
- Table 33: Leading Glaucoma Pharmaceutical Products in The US (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/Xalcom, Cosopt, Lumigan, Travatan, Alphagan, Combigan, Generic Timolol and Others (Includes Corresponding Graph/Chart)
- Select Glaucoma Pharmaceuticals Presently Approved/ in Pipeline
- Table 34: Top 10 Brands of Eye/Lens Care in The US: Breakdown of Dollar and Unit Sales through Drug Stores, Supermarkets and Discount Stores for The Year Ended November 2007 (in US$ 000 and Thousand Units)
- Table 35: Top 5 Eye Care Products in The US: Breakdown of Dollar Sales through Food, Drug and Mass Market Channels for The Year Ended July 2007 (in US$ Million) (Includes Corresponding Graph/Chart)
- Table 36: Age-Related Wet Macular Degeneration Market in The United States (2004-2006): Percentage Market Share Breakdown of Leading Players - Qlt Inc/Novartis Pharmaceutical Corp, and Eyetech Pharmaceuticals (Osi) / Pfizer. (Includes Corresponding Graph/Chart)
- Table 37: Ocular Allergy Market in The United States (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Novartis Pharmaceutical, Bausch & Lomb Pharmaceuticals, Allergan, Santen, and Others (Includes Corresponding Graph/Chart)
- Table 38: Ocular Nsaids (Topical Non-Steroidal Anti-Inflammatory Drugs) Market in The United States (2007): Percentage Market Share Breakdown of Leading Players - Allergan, Inc. Novartis Pharmaceutical Corp., Alcon Laboratories, Inc., and Ista Pharmaceuticals (Includes Corresponding Graph/Chart)
- Table 39: Age-Related Macular Degeneration Market in The United States (2006, 2009 & 2012): Dollar Sales of Major Branded Drugs – Visudyne, Macugen, and Lucentis (in US$ Million) (Includes Corresponding Graph/Chart)
- Major Anti-Glaucoma Drugs Available in The United States: Year 2006
- Major Drugs Available in The United States for The Treatment of Amd: Year 2005
- Drugs in The Pipeline for The Treatment of Amd in The United States: Year 2005
- Major Drugs Available in The United States for The Control of Dry Eye: Year 2005
- US Market for Dry Eye: Drugs in The Pipeline Year 2005
- Companies Actively Involved in Manufacturing Drugs for Dry Eye: Year 2005
- Major Drugs Available in The United States for The Treatment of Ocular Allergies: Year 2005
- US Market for Ocular Allergies: Drugs in The Pipeline: Year 2005
- Statistical Findings on Ophthalmic Diseases in The United States
- Table 40: Prevalence of Age-Related Macular Degeneration: Percentage Breakdown by Wet Amd & Intermediate Dry Amd by Age Group for The Year 2005 (Includes Corresponding Graph/Chart)
- Table 41: Prevalence of Age-Related Wet Macular Degeneration in The United States for The Years 2006, 2009, & 2012 (in Millions of Individuals) (Includes Corresponding Graph/Chart)
- Table 42: Number of Individuals Treated for Wet Amd in The United States (in Thousands) for The Years 2006, 2009 & 2015 (Includes Corresponding Graph/Chart)
- Table 43: Prevalence of Ocular Hypertension (Oht) in The United States for The Years 2006, 2009, & 2011 (in Millions of Individuals) (Includes Corresponding Graph/Chart)
- Table 44: Prevalence of Primary Open Angle Glaucoma (Poag) in The United States for The Years 2006, 2009, & 2011 (in Millions of Individuals) (Includes Corresponding Graph/Chart)
- Table 45: Prevalence of Normal Tension Glaucoma (Ntg) in The United States for The Years 2006, 2009, & 2011 (in Thousand Individuals) (Includes Corresponding Graph/Chart)
- Table 46: Prevalence of Exfoliative Glaucoma (Eg) in The United States for The Years 2006, 2009, & 2011 (in Thousand Individuals) (Includes Corresponding Graph/Chart)
- Table 47: Prevalence of Pigmentary Glaucoma (Pg) in The United States for The Years 2006, 2009, & 2011 (in Thousand Individuals) (Includes Corresponding Graph/Chart)
- Table 48: Number of Individuals Treated for Glaucoma in The United Sates (2006, 2009 and 2011): Breakdown by Type - Ocular Hypertension (Oht), Primary Open Angle Glaucoma (Poag), Normal Tension Glaucoma (Ntg), Pigmentary Glaucoma (Pg) and Exfoliative Glaucoma (Eg) (in 000 Individuals) (Includes Corresponding Graph/Chart)
- Table 49: Prevalence of Ocular Allergy in The United States for The Years 2006, 2009, & 2012 (in Millions of Individuals) (Includes Corresponding Graph/Chart)
- Table 50: Number of Individuals Treated for Ocular Allergy in The United States (in Million) for The Years 2006, 2009 & 2012 (Includes Corresponding Graph/Chart)
- Table 51: Prevalence of Cataract in The United States: Percentage Breakdown by Age Group for The Year 2005 (Includes Corresponding Graph/Chart)
- Table 52: Prevalence of Cataract in The United States for The Years 2006, 2009, & 2012 (in Millions of Individuals) (Includes Corresponding Graph/Chart)
- Table 53: Number of Individuals Treated for Cataract with Ocular Nsaids (Topical Non- Steroidal Anti-Inflammatory Drugs) in The United States for The Years 2006, 2009 & 2012 ((in Millions) (Includes Corresponding Graph/Chart)
- Table 54: Prevalence of Dry Eye in The United States for The Years 2006, 2009, & 2012 (in Millions of Individuals) (Includes Corresponding Graph/Chart)
- Table 55: Number of Individuals Treated for Dry Eye in The United States (in 000s) for The Years 2006, 2009 & 2012 (Includes Corresponding Graph/Chart)
- B. Market Analytics
- Table 56: US Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 57: US Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 58: US 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (Includes Corresponding Graph/Chart)
- 13.Canada
- A. Market Analysis
- Outlook
- Lack of Awareness: A Key Issue
- B. Market Analytics
- Table 59: Canadian Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 60: Canadian Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 61: Canadian 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (Includes Corresponding Graph/Chart)
- 14.Japan
- A. Market Analysis
- Outlook
- Growth Drivers
- Market Data Statistics
- Leading Ophthalmic Pharmaceutical Brands in The Market
- Table 62: Japanese Market for Prescription Ophthalmic Drugs: Percentage Breakdown by Therapeutic Area – Glaucoma, Infection, Corneal Disorder, Ocular Allergy, Surgical Preparation, Steroid, Cataract, and Others. (Includes Corresponding Graph/Chart)
- B. Market Analytics
- Table 63: Japanese Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 64: Japanese Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 65: Japanese 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (Includes Corresponding Graph/Chart)
- 15.Europe
- A. Market Analysis
- Outlook
- A Market Primer
- Drug Reimbursement in Europe
- B. Market Analytics
- Table 66: European Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Country/Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 67: European Historic Review for Ophthalmic Pharmaceutical Drugs by Country/Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 68: European 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Country/Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- Table 69: European Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 70: European Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 71: European 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (Includes Corresponding Graph/Chart)
- 15a.France
- A. Market Analysis
- Outlook
- B. Market Analytics
- Table 72: French Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 73: French Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 74: French 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (Includes Corresponding Graph/Chart)
- 15b.Germany
- Market Analysis
- Table 75: German Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 76: German Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 77: German 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- 15c.Italy
- Market Analysis
- Table 78: Italian Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 79: Italian Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 80: Italian 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- 15d.The United Kingdom
- A. Market Analysis
- Outlook
- B. Market Analytics
- Table 81: UK Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 82: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 83: UK 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- 15e.Spain
- A. Market Analysis
- Outlook
- How & Why The Health Insurance System in Spain Is Conducive?
- Pharmaceutical Reimbursement Reforms in Spain (1996-2002)
- B. Market Analytics
- Table 84: Spanish Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 85: Spanish Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 86: Spanish 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (Includes Corresponding Graph/Chart)
- 15f.Rest of Europe
- A. Market Analysis
- Outlook
- B. Market Analytics
- Table 87: Rest of Europe Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 88: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 89: Rest of Europe 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- 16.Asia-Pacific
- A. Market Analysis
- Outlook
- B. Market Analytics
- Table 90: Asia-Pacific Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 91: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 92: Asia-Pacific 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (Includes Corresponding Graph/Chart)
- 17.Latin America
- Market Analysis
- Table 93: Latin American Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 94: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 95: Latin American 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- 18.Rest of World
- A. Market Analysis
- Outlook
- B. Market Analytics
- Table 96: Rest of World Recent past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
- Table 97: Rest of World Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
- Table 98: Rest of World 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-Allergy, Anti-Infective, Dry Eye, Anti-Inflammation, Back of Eye and Others for Years 2005, 2010, and 2015 (Includes Corresponding Graph/Chart)
- Competition
- Total Companies Profiled: 95 (Including Divisions/Subsidiaries - 126)
- Region/Country/Players
- The United States
- Canada
- Japan
- Europe
- France
- Germany
- The United Kingdom
- Italy
- Spain
- Rest of Europe
- Asia-Pacific (Excluding Japan)
- Latin America
- Middle-East